Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
MoneyMax 1H FY26 profit attributable to owners jumps 77.3% to S$52.55 million; revenue rises 34.1% to S$325.7 million

MoneyMax 1H FY26 profit attributable to owners jumps 77.3% to S$52.55 million; revenue rises 34.1% to S$325.7 million

ReutersReuters2026/08/11 10:57
  • MoneyMax 1H-2026 profit attributable to owners climbed 77.3% to S$52.55 million.
  • Revenue rose 34.1% to S$325.73 million; profit before income tax increased 73.2% to S$69.49 million.
  • Pawnbroking revenue jumped 60.1% to S$69.2 million on higher interest income; retail and trading of gold and luxury items revenue rose 30.6% to S$245 million.
  • Interim tax-exempt dividend declared at 0.25 Singapore cent per share.
  • Store count reached 139 after 26 openings year-to-date; another 10 stores planned by year-end, subject to approvals and readiness.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MoneyMax Financial Services Ltd. published the original content used to generate this news brief via Singapore Exchange Limited (SGX) (Ref. ID: LAOIGAAQH44NI7FN) on August 11, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Electra Therapeutics (ETRA.US) submits US IPO application, leveraging the biotech IPO boom to advance new drug development for immune diseases and cancer.

Electra Therapeutics Inc. has officially filed for an initial public offering (IPO), aiming to leverage the strong IPO performance of the biotechnology sector this year to raise funds for its clinical-stage pipeline of drugs targeting immune-mediated diseases and cancer.

智通财经2026/08/29 03:22
Electra Therapeutics (ETRA.US) submits US IPO application, leveraging the biotech IPO boom to advance new drug development for immune diseases and cancer.